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Pharmacological evaluation of the effects of phenylcarbamic 
acid derivatives on cardiovascular functions in rats
Four phenylcarbamic acid derivatives, (1-(4-fluorophenyl)-
4-[3-(4-methoxyphenylcarbamoyloxy)-2-hydroxypropyl]pi-
perazinium chloride (1), (1-(2-methylphenyl)-4-[3-(4-methoxy-
phenyl carbamoyloxy)-2-hydroxypropyl]piperazinium 
chlo ride) (2), (1-(2-methylphenyl)-4-[3-(4-ethoxyphenyl car-
bamoyloxy)-2-hydroxypropyl]piperazinium chloride) (3) and 
(1-(3-trifluoromethylphenyl)-4-[3-(4-methoxyphenylcar-
bamoyl oxy)-2-hydroxypropyl]piperazinium chloride) (4) were 
investigated for their ability to affect various cardiovascular 
functions and to establish their chemical structure-biological 
activity relationship. The compounds were evaluated for their 
antiarrhythmic efficacy using ouabain-induced rhythm dis-
turbances and the ability to inhibit the positive chronotropic 
effect of isoproterenol in isolated atria of Wistar rats. Electro-
cardiogram (ECG) parameters in isolated hearts of sponta-
neously hypertensive rats (SHR) perfused according to the 
Langendorff method and ability to decrease phenylephrine-
-induced contraction of the aortic strips after repeated admini-
stration of the compounds were also analyzed. Only com-
pound 3 delayed significantly the evaluated para meter of 
arrhythmogenicity and was able to antagonize the isoprotere-
nol-induced positive chronotropic effect in normotensive 
rats’ atria. Similarly, in SHR rats, only compound 3 was able 
to decrease heart frequency significantly without influenc-
ing the duration of QT (time between the start of the Q wave 
and the end of the T wave) and QTc (frequency corrected QT) 
intervals. The evaluated endothelial function was improved 
after administration of compound 2. Fluorine-containing 
structures (1 and 4) were less effective compared to 2 -́methyl-
phenylpiperazine derivatives (2 and 3). The latter two com-
pounds showed suitable efficacy, which supported their use 
for futher pharmacological research.
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b-blockers (BBs) are an essential component of medical therapy, mainly in patients 
with various cardiovascular diseases of any genesis. The condition for a proper b-blocking 
effect is the aryloxyaminopropanol skeleton and the activity maintained even in a broader 
spectrum of substituted aromatic nuclei, as well as unsubstituted ones, and also in different 
substituents on the basic nitrogen of these compounds. Molecular studies with phenoxy-
aminopropanols confirmed increased cardioselectivity for para-substituted derivatives (1). 
Other studies described changes in the quality of biological activity due to modification in 
the connecting chain and in the salt forming fragment of N-methylpiperazine-derivatives 
(2). Compounds that contain substituted N-phenylpiperazine moiety markedly antagonize 
the α-adrenergic receptors, which allows design of therapeutically active mole cules able 
to block both types of adrenoceptors. Substitution of the phenyl nucleus in the lipophilic 
part of the molecule in ortho- or meta-position enhanced the b-blocking effect while the 
substitution in para-position caused a decrease in activity. Cardioselectivity or additional 
α-blocking properties could be achieved by modifying the salt forming part of the molecule, 
when the substituent attached to nitrogen becomes a part of the aminopropanol linking 
chain (3). In addition, lipo-hydrophilic properties and other pharmacokinetic differences 
also contribute significantly to various effects of BBs (4). 
The rationale of the tested compounds design was the assumed affinity for both b- 
and particularly α1-adrenoceptors because of therapeutically effective phenylpiperazine-
containing selective α-adrenolytics (5). Modification of the primary aryloxyaminopropa-
nol structure of BBs by incorporation of the carbamoyl (-NH-CO-) group on the bridge 
linking the phenyl nucleus to the N-phenylpiperazine moiety was made in an attempt to 
confirm and/or influence the b-blocking efficacy of the compounds. Although the basic 
b-adrenolytic effects were also noticed in the modified structures, they were found to be 
approximately 10-times weaker than in the original aryloxyaminopropanols (6).
In our experiments, we used the b-adrenoceptor antagonists carvedilol and metopro-
lol as positive controls. Carvedilol is the third generation of nonselective b-blockers with 
moderate α1-receptor blocking ancillary vasodilator and cardioprotective properties (7). 
Metoprolol is currently used in clinical practice for the treatment of arrhythmia as well as 
for improving cardiac autonomic function (8). 
In this paper, we present the basic data on four phenylcarbamoyloxy-2-hydroxy-N-
phenylpiperazine derivatives, bearing in their molecule the potential b-adrenoceptor 
blocking structural configuration combined with vasodilatory and cardioprotective com-
ponents. The basic pharmacological properties such as specific antiisoproterenol and an-
tiarrhythmic activities were first screened in Wistar rats. In the following phase of the 
study, some electrical parameters of the heart and the potential antihypertensive effect of 
the chosen compounds on spontaneously hypertensive rats (SHR) were also evaluated.
EXPERIMENTAL
Chemistry
The evaluated compounds (1-(4-fluorophenyl)-4-[3-(4-methoxyphenylcarbamoyloxy)-
2-hydroxypropyl]piperazinium chloride) (1) (1-(2-methylphenyl)-4-[3-(4-methoxy-
phenylcarbamoyloxy)-2-hydroxypropyl]piperazinium chloride) (2) (1-(2-methylphenyl)-
4-[3-(4-ethoxyphenylcarbamoyloxy)-2-hydroxypropyl]piperazinium chloride) (3) and 
(1-(3-trifluoromethylphenyl)-4-[3-(4-methoxyphenylcarbamoyloxy)-2-hydroxypropyl]pipera-
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zinium chloride) (4) (Fig. 1) were synthesized by the reaction of 1-(4-fluorophenyl)-, 2-methyl- 
or 3-trifluoromethyl)phenylpiperazin-1-yl- moiety with the corresponding 2,3-epoxypropan-
-1-yl esters of 4-alkoxyphenylcarbamic (alkoxy = methoxy or ethoxy) acid according to the 
literature (9). Derivatives were synthesized as racemates containing one stereogenic center. 
The obtained basic esters were not crystalline substances. The final compounds were isolated 
as salts of hydrochloric acid. Physicochemical properties of the compounds were evaluated 
by standard analytical methods and are reported in the relevant literature (10).
Fig. 1. Chemical structures and molecular masses of the test compounds 1–4.
Pharmacological evaluation
Animals. – All three-month-old rats used in the experiments were obtained from the 
breeding station Dobra Voda (Slovak Republic). Animals were allowed to acclimatize to 
the housing conditions with free access to food and tap water for at least seven days. The 
investigation conformed to the Guide for the Care and Use of Laboratory Animals pub-
lished in the Collection of Laws of the Slovak Republic and was approved by the Ethics 
Committee of the Faculty of Pharmacy, Comenius University, and by the State Veterinary 
and Food Administration of the Slovak Republic.
Antiisoproterenol activity on isolated atria. – Male Wistar rats were anesthetized with 
thiopental sodium (45 mg kg–1 bm, 5 % solution, i.p., Biochemie GmbH, Austria). The hearts 
were separated, right atria were then isolated and connected to an isometric transducer in 
tyrode solution (composition in mmol L–1: NaCl 137.0, KCl 2.7, NaHCO3 25, MgCl2 1.0, 
 NaH2PO4 0.42, CaCl2 1.9, glucose 11.0) at 30 °C under resting tension of 1 g and saturated 
with pneumoxide (O2 and 5 % CO2). The preparation was allowed to stabilize for at least 
30 min. Then, isoproterenol chloride was added in increased concentrations (10–11 – 10–5 mol L–1) 
and the concentration-response curve (CRC) was plotted. After the atria were washed and 
allowed to re-equilibrate, test compounds (1 × 10–6 mol L–1 and/or standard carvedilol 
1 × 10–7 mol L–1) (carvedilol substance was a kind gift from Zentiva, Slovak Republic) were 
added to the bath 20 min before the second CRC was obtained and changes in the heart 
rate were registered. The affinity for isoproterenol was expressed as EC50 (agonist concen-
tration producing 50 % of maximum response). The antagonist potency of the compounds 
was calculated from the shift in CRC of isoproterenol and expressed as dissociation con-
stants (pA2 values), i.e., negative logarithm of the antagonist molar concentration that 
caused twofold inhibition in isoproterenol response curves (11).
Ouabain-induced arrhythmia in rats. – Male Wistar rats were anesthetized with tribro-
moethanol (Avertin, Generics, UK, 375 mg kg–1, i.p.). Cardiac rhythm disturbances were 
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induced by infusing ouabain (Sigma- Aldrich, USA) solution into the femoral vein (82 µg 
min–1) and were recorded by an electrocardiograph. Evaluated compounds and/or meto-
prolol, both at a concentration of 1 × 10–6 mol kg–1, were administered i.v. (metoprolol suc-
cinate, Sigma-Aldrich) five minutes before ouabain infusion. Increase in the threshold 
dose of ouabain which induced ventricular extrasystoles, fibrillation and cardiac arrest 
indicated the antiarrhythmic effect. The threshold dose of ouabain needed to induce dif-
ferent cardiac disturbances was determined and expressed in µg kg–1 bm (6).
Measurement of vascular contractility in vitro. – Control male SHR rats (n = 8) and control 
male Wistar rats (n = 6) received subcutaneously saline as vehicle for seven days, making 
two negative control groups. The other three SHR groups (marked 1, 2, 3, n = 8) received 
the test compounds subcutaneously in a dose of 1 mg kg–1 bm (dissolved in saline) for 
seven consecutive days. The last group of hypertensive animals received carvedilol orally 
(Carvedilol Teva, Teva B.V., The Netherlands, n = 6) in a dose of 12.5 mg kg–1 for seven con-
secutive days. 
Determination of vascular contractility was carried out as described by Racanska et 
al. (6). Briefly, after rats were sacrificed (5 % thiopental, 80 mg kg–1 bm, i.p., Biochemie 
GmbH, Austria), the thoracic aorta was excised from the diaphragm to the arch and placed 
into an isolated tissue bath containing Krebs-Henseleit (K-H) solution. Three-millimeter-
long segments were cut from the aorta and placed between two stainless steel hooks in-
serted into the lumen and placed into the apparatus for isolated organs (TSZ-04 Multi 
Chamber Tissue Bath, Experimetria, Hungary) for isometric tension recordings. The endo-
thelial function was measured as contraction responses induced by phenylephrine (10–5 
mol L–1, Sigma-Aldrich) and relaxation responses induced by acetylcholine (10–5 mol L–1, 
Sigma-Aldrich). The responses were transferred as digital signals (FSG-01 Force/displace-
ment transducer, Experimetria) and recorded with the S.P.E.L. Advanced ISOSYS software 
(Experimetria). The presented data are expressed as average values of the animals in the 
group; three recordings were taken from each animal.  
Measurement of cardiac electrical parameters. – The isolating procedure was carried out 
as described by Kralova et al. (12). Briefly, the rats were anesthetized with thiopental so-
dium (45 mg kg–1 bm, i.p., 5 % solution, Biochemie GmbH). After chest opening, the heart 
was separated and immersed into a cold (4 °C) K-H solution where a cannula was inserted 
into the aorta and fixed with a silk ligature. The heart was placed in the organ chamber of 
a Langendorff apparatus and retrogradely perfused with K-H solution in constant pres-
sure mode (90–100 cm H2O). On isolated spontaneously beating hearts, a one-lead ven-
tricular ECG was recorded in vitro using a pair of wire electrodes (ECG MLA 1213 Needle 
Electrodes for FE 136, ADInstruments, Germany) impaled into the LV free wall. Frequency 
corrected QT intervals (QTc) were derived using modified Bazett’s formula (13):
QTc = measured QT/√(RR/200)
where, QT is the time between the start of the Q wave and the end of the T wave, RR is the 
time between beats, the heart rate.
Statistical analysis
Results are expressed as mean ± standard error of the mean (SEM). Means were com-
pared using Student’s unpaired t-test (isolated atria). One-way analysis of variance (ANO-
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VA) followed by the LSD (least significant difference) post-hoc test was used to assess the 
presence of significant differences in the remaining experiments. Values were considered 
statistically significant when p < 0.05. 
RESULTS AND DISCUSSION
In this work, we evaluated the biological efficacy of four original compounds in which the 
basic aryloxyaminopropanol structural moiety proper for all clinically used b-blockers was 
modified. In the first part of the experiment (screening), we evaluated how the extension of the 
connecting chain between lipo- and hydrophilic parts of the molecule contributed to specific 
antiisoproterenol (potential b-adrenolytic) as well as antiarrhythmic activity of the com-
pounds. In the second part of the study, we excluded compound 4 because of its low biological 
efficiency observed in previous experiments; thus, compounds 1, 2 and 3 were measured for 
some other cardiovascular parameters.
Antiisoproterenol activity on isolated atria
We evaluated how extension of the chain linking, lipo- and hydrophilic part of the mol-
ecule, contributed to specific antiisoproterenol efficacy of the compounds. Carvedilol was 
used as a positive control. Antiisoproterenol activity of the compounds on the heart rate was 
examined in vitro in spontaneously beating right atria of rats and expressed as EC50 values, 
from which pA2 values were calculated. All the evaluated compounds confirmed the effect 
when their calculated pA2 values varied in the range of 5.23–7.41 (Table I). Then, compared 
to the used b-blocker, the carvedilol, compounds 2 and 3 showed a moderate effect (p < 0.05, 
p < 0.01, resp.) and only a slight effect was detected for analogues bearing a fluorine and/or 
trifluoromethyl group in the piperazine ring (compounds 1 and 4).
Table I. Effective concentrations (EC50) of isoproterenol for the  atria heart rate before and after incubation 
with the evaluated compounds and their pA2 values
Compd. EC50 (isoproterenol, mol L–1)    pA2  
Control (5.38 ± 1.99) × 10–11
   6.83 ± 0.33
1a (4.99 ± 1.99) × 10–10
Control (9.43 ± 0.90) × 10–11
   7.41 ± 0.35
2a (3.66 ± 1.63) × 10–9*
Control (3.08 ± 1.30) × 10–11
   7.22 ± 0.25
3a  (4.12 ± 1.17) × 10–10**
Control (3.73 ± 1.55) × 10–10
5.23 ± 0.38
4a (8.55 ± 2.69) × 10–10
Control (8.05 ± 1.93) × 10–10
 8.15 ± 0.49
Carvedilolb (1.88 ± 0.65) × 10–8**
Incubation with: a 10–6 mol L–1, b 10–7 mol L–1. Control for: evaluated compounds saline, carvedilol: DMSO+saline.
Data are expressed as mean ± SEM, n = 6. Significant difference vs. control: * p < 0.05, ** p < 0.01. For chemical struc-
tures see Fig. 1.
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Ouabain-induced arrhythmias in rats
In the present study, it was found that only compound 3 with a methyl group in posi-
tion-2 of the phenyl-N-piperazine part of the molecule, delayed significantly (p < 0.05, p < 
0.01 and p < 0.001) the evaluated parameters of arrhythmogenicity (Fig. 2). Compound 2 
which differs only in alkoxy substituent in the phenylcarbamoyl acid counterpart of the 
molecule (-OCH3 instead of -OC2H5) affected the ouabain cardiotoxicity (fibrillation and 
cardiac arrest) non-significantly. From the tested compounds, compounds 4 and 1 seem to 
be the least anti-oubain active. However, no significant differences among all test com-
pounds were observed. None of the test compounds exceeded the efficacy of the used 
positive control, metoprolol. The obtained results are in accord with our previous studies 
where the compounds with 4-fluorophenyl and 2- or 4-alkoxy-substitution decreased 
slightly the amount of infused cardiotoxic ouabain needed for the first signs of arrhyth-
mogenicity. Comparison of the current results to the values of anti-ouabain activity of 
structurally related compounds led to the conclusion that the bulky substituent attached 
to the phenylpiperazine moiety together with the extended carbamoyloxyaminopropanol 
chain reduced their antiarrhythmic properties (6).
Fig. 2. Protection provided by test compounds 1–4 and metoprolol at the concentration 1 × 10–6 mol kg–1 
against ouabain-induced arrhythmia in anesthetized rats. Data are expressed as mean ± SEM, n = 7. 
Significant difference vs. control: * p < 0.05 ,** p < 0.01, *** p < 0.001. For chemical structures see Fig. 1.
Measurement of vascular contractility in vitro
To demonstrate the effects of the compounds on the endothelial function, we mea-
sured the contractile and relaxation responses of the thoracic aorta. We assessed an an-
tagonistic effect of the compounds against the constriction induced by the α1-adrenergic 
agonist phenylephrine, as well as the relaxation induced by acetylcholine on isolated aor-
tic rings. SHR aortic rings showed increased contractile responses compared to Wistar rats, 
which could indicate endothelial damage as a result of hypertension (Fig. 3). The relaxation 
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response of SHR aortic rings induced by acetylcholine was unchanged compared to the 
rings from normotensive rats. One week administration of compounds 1 and 2 signifi-
cantly (p < 0.05, p < 0.01, resp.) improved the contractive response of aortic rings in SHR 
compared to SHR without treatment but not so effectively as carvedilol. We could suppose 
that 2-methyl-substitution on the phenyl-N-piperazine part in compound 2 was responsi-
ble for a more desirable effect on vessels. It is obvious that damage of the endothelium 
caused by hypertension worsened the dilatatory ability of aortic rings. However, none of 
the evaluated substances improved relaxation of the aorta significantly.
Measurement of electrical activity on isolated rat heart
Bradycardia induced by b-blockers may be beneficial for protecting myocytes through 
improvement of the relationship between the myocardial blood flow and oxygen con-
sumption (14). Our results showed no significant differences between the Wistar control 
and SHR control rats (Table II). Administration of compounds 2 and 3 resulted in a sig-
nificant (p < 0.05) decrease of heart frequency compared to SHR without pretreatment. 
However, all the evaluated substances were less effective than the used standard carvedilol. 
Administration of the above-mentioned compounds did not change the duration of QT 
and QTc intervals. On the basis of their chemical structure and our previous experiments 
of the negative chronotropy of structurally similar compounds, it could be presumed that 
compounds 2 and 3 are able to act via inhibition of cardiac b-adrenoceptors (11). Various 
experiments with hypertensive SHR animals showed a prolongation of the QT and QTc 
intervals related to the slowed ventricular conduction compared to conventional Wistar 
animals (15). In our experiment, however, the tested compounds failed to shorten the dura-
tion of QT and QTc intervals.
Fig. 3. Contraction and relaxation responses of aortal rings from normotensive Wistar rats (n = 6), 
hypertensive rats (SHR, n = 8), SHR rats pretreated with compound 1, 2 or 3 (n = 8) and carvedilol rats 
(n = 6), of phenylephrine-induced contraction and maximum relaxation after administration of ace-
tylcholine. Data are expressed as mean ± SEM. Significant difference vs. SHR: * p < 0.05 , ** p < 0.01, 
*** p < 0.001. For chemical structures see Fig. 1.
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CONCLUSIONS
We may conclude that all the evaluated compounds, designed and synthesized as po-
tential b-blockers, exhibited only moderate cardiovascular effects. Due to antiisoproterenol 
activity in rats’ atria and ability to inhibit ouabain-induced heart disturbances, only com-
pound 3 could be assumed to be a potential b-blocking agent. In SHR, only compound 2 
improved significantly the contractile properties of the aorta. It seems that participation of 
α-adrenoceptor inhibition might be responsible for this effect. Heart frequency measured on 
isolated hearts from SHR rats was significantly decreased by compounds 3 and 2. According 
to the obtained results, it is obvious that substitution of phenyl-N-piperazine by the 2-meth-
yl group (compounds 2 and 3) was more effective than the fluorine analogues. The presence 
of fluorophenyl- or trifluoromethylphenyl-moiety on the piperazine ring in compounds 1 
and 4, resp., does not seem suitable for the postulated properties of the compounds.
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